How to Evaluate Healthcare AI Vendor Testing

TL;DR

• Evaluate a healthcare AI vendor on how they test, not how they demo. Ask for scenario counts, interface coverage, failure catalogs, regression evidence, and transparent reports. Mature vendors produce this in minutes, not weeks.
• Only 16% of health systems report measurable value from AI deployments, per KLAS Research 2024. Testing rigor is the single factor most correlated with the other 84% avoiding production surprises.
• 94% of physicians say prior authorization delays have caused adverse clinical events (AMA 2024). A vendor without a payer portal regression suite will transfer that risk to you.
• Use a 1 to 5 scoring framework across five categories. A vendor scoring below 3 in any category must have a credible plan to close the gap before contract.

The testing question most buyers skip

When health systems evaluate an AI vendor, conversations center on clinical accuracy, integration timelines, and price. One question gets skipped: how does the vendor test the product before it touches your patients?

The answer reveals more than any demo. A vendor with rigorous, repeatable testing infrastructure is far more likely to deliver a product that works on day one and keeps working when payer portals change, EHR configurations shift, or patient populations differ from training data.

This article gives a framework for clinical informatics leaders, CIOs, and governance committee members making purchasing decisions.

"We stopped asking vendors 'how accurate is your model?' and started asking 'show us your failure mode catalog.' It changed which vendors we picked, and it changed our post-go-live incident rate."

Aneesh Chopra, former US CTO, White House

Why testing beats demo performance

Every vendor has a polished demo. The demo runs against a controlled dataset, a known patient, a predictable payer, and a scripted workflow. Production is not that. Production means thousands of patients, varied insurance, dozens of payer portals with different layouts, EHR configurations that vary by department, and edge cases no one anticipated.

The gap between a demo environment and a real sandbox is where failures hide. The vendor's testing methodology tells you whether they have systematically explored that gap.

Red flags in vendor demos

Small, static patient populations

If the demo always uses the same three patients, ask why. Real agents need to handle patients across age, insurance, complexity, and demographics. A static dataset means the product has not been validated against your population diversity.

No failure scenarios shown

A confident vendor shows what happens when things go wrong. If the demo is all happy path, ask for failure handling. What happens when the portal is down? When insurance has lapsed? When FHIR returns an unexpected error? Missing failure documentation is itself a failure.

Single-interface demos

Healthcare workflows rarely involve one system. A prior auth submission may require FHIR reads, IVR calls, portal logins, and document upload. Demonstrating one interface in isolation suggests the vendor has not tested the multi-interface interactions where most production failures happen.

Vague testing infrastructure answers

Ask: "How many test scenarios do you run before each release?" Vague ("we do extensive testing") versus specific ("340 scenarios across 12 payer configurations before every deployment") tells you about testing maturity.

No regression testing

Payer portals update layouts. EHRs release new API versions. IVR menus get restructured. A vendor that cannot describe automated regression testing is discovering breakage from customer complaints.

Questions to ask during evaluation

Scenario coverage

• How many distinct test scenarios run against the product?
• What patient populations are represented (age, insurance, complexity, language)?
• Are scenarios hand-crafted, template-generated, or derived from production patterns?
• Can you provide a coverage report by payer, procedure, and clinical condition?

Interface coverage

• Which interfaces (FHIR R4, IVR, portals, HL7v2, X12 278, fax)?
• Tested in isolation or combination?
• How do you simulate payer portals that change frequently?
• Do you test against multiple EHR configurations?

Failure documentation

• What failure modes are documented for this product?
• For each, what is the expected agent behavior?
• Can you share the catalog?
• How do you discover new modes, systematic process or production incidents?
• For prior auth, how well do you understand common failure patterns?

Patient population diversity

• How many patient profiles in your test suite?
• Edge cases: multiple coverage, recent changes, pediatric, rare conditions?
• How do you validate consistency across demographic groups?
• Non-English scenarios for multilingual products?

Change and regression

• How fast do you detect a payer portal change?
• Process for updating scenarios on payer policy changes?
• Regression scope and frequency?
• Can you show history of issues caught before production?

A scoring framework for testing rigor

Score each category 1 to 5.

Scenario depth

• 1: Under 10 scenarios, manually maintained
• 2: 10 to 50 covering core workflows
• 3: 50 to 200 with payer coverage
• 4: 200 to 500 with automated generation and population diversity
• 5: 500+ with continuous expansion from production patterns

Interface breadth

• 1: Single interface
• 2: Two in isolation
• 3: Multiple in isolation with some integration
• 4: Full multi-interface with realistic sequences
• 5: Multi-interface with fault injection (portal outages, FHIR errors, IVR changes)

Failure documentation

• 1: None
• 2: Ad hoc list
• 3: Structured catalog with expected behavior
• 4: Catalog plus tests and severity ratings
• 5: Catalog with historical detection rates, resolution times, and incident correlation

Regression coverage

• 1: None
• 2: Basic smoke tests
• 3: Automated suite per release
• 4: Continuous with external-system change detection
• 5: Continuous, automated alerts on external changes, history shared with customers

Evidence transparency

• 1: None shared
• 2: Verbal descriptions during sales calls
• 3: Summary reports on request
• 4: Detailed reports with scenario counts and coverage
• 5: Real-time access plus published methodology

A vendor scoring 3+ in every category has a mature practice. Below 3 in any should have a specific plan to close the gap.

What governance committees should require

Pre-contract

• Written testing methodology with scenario counts and interface coverage
• Sample report with pass/fail rates
• Product-specific failure mode catalog
• Regression process and frequency
• Evidence of HIPAA-compliant testing without real patient data

Pre-deployment

• Tests configured to your EHR version, payer mix, and workflows
• Validated against your top 10 payers by volume
• Failure mode review with your clinical informatics team
• Expected behavior documented for each known mode
• Agreed-upon thresholds (error rate, completion, latency) and measurement methodology

Ongoing

• Monthly or quarterly regression reports
• Notification process for external system changes
• Annual methodology review with continuous-improvement evidence
• Access to incident reports correlating production issues to testing gaps

The evidence package a good vendor provides

A mature vendor provides these without weeks of prep:

• Methodology document. How testing works, tools used, scenario generation, evaluation. Should reference evaluation approaches measuring operational correctness, not only clinical accuracy.
• Scenario coverage report. Generated from actual runs, not assembled for sales.
• Failure mode catalog. 50+ documented modes suggests a vendor that understands the space. Fewer than 10 suggests they have not looked, or will not share.
• Regression history. Examples of external changes caught by tests before customers reported them.
• Test environment access. Observe testing live, or run your own scenarios in a sandbox.

Key Takeaways

• Testing methodology correlates with production reliability more than any other vendor attribute.
• Score five categories (depth, breadth, failure docs, regression, transparency) on a 1 to 5 scale.
• Require specific numbers, not vague descriptions. "340 scenarios across 12 payers" is mature; "we test extensively" is not.
• Multi-interface testing with fault injection separates top vendors from the rest.
• A failure mode catalog with 50+ entries signals a vendor that has looked seriously at production risk.
• Pre-contract, pre-deployment, and ongoing requirements all belong in your governance checklist.
• A vendor that can produce the evidence package in hours has done the work. A vendor that takes weeks has not.

FAQ

What is the single most important question to ask?

"Show me your failure mode catalog." A vendor that maintains 50+ documented failure modes with expected behaviors has invested in production readiness. A vendor that cannot produce one has optimized for demos.

How many test scenarios is enough?

It depends on interface scope. A single-interface FHIR product might ship safely at 200+ scenarios. A multi-interface prior auth agent that touches FHIR, IVR, and 10 payer portals needs 500+ at minimum, covering combinations, not just each interface individually.

Does clinical accuracy still matter?

Yes, but it is necessary and not sufficient. Per AMA 2024, 94% of physicians report prior auth delays have caused adverse events. An accurate agent that fails operationally transfers that risk to patients. Operational correctness belongs in the same scorecard as clinical accuracy.

What if a vendor refuses to share their test reports?

Treat that as a scoring-category 1 or 2. Reputable vendors share summary reports with prospects under NDA. Per HIMSS 2024 guidance on AI procurement, evidence transparency is a baseline expectation for any healthcare AI contract.

How often should ongoing testing evidence be delivered?

Monthly is ideal for agents in production, quarterly is acceptable for lower-risk read-only products. Either way, you want automated regression results, new failure modes discovered, and any correlations between test gaps and production incidents.